You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

Drug Price Trends for ARTHRITIS PAIN RELIEVER


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for ARTHRITIS PAIN RELIEVER

Average Pharmacy Cost for ARTHRITIS PAIN RELIEVER

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
ARTHRITIS PAIN RELIEVER 1% GEL 70000-0555-01 0.10989 GM 2025-01-22
ARTHRITIS PAIN RELIEVER 1% GEL 70000-0555-02 0.08614 GM 2025-01-22
ARTHRITIS PAIN RELIEVER 1% GEL 70000-0555-03 0.06882 GM 2025-01-22
ARTHRITIS PAIN RELIEVER 1% GEL 70000-0555-01 0.10832 GM 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Arthritis Pain Relievers

Introduction to Arthritis Pain Relievers

Arthritis pain relievers are a crucial segment of the broader pharmaceutical market, addressing the growing need for effective pain management solutions. This market is driven by several key factors, including the increasing prevalence of arthritis, advancements in medical technology, and the rising demand for both opioid and non-opioid treatments.

Market Size and Growth

Current Market Size

The global market for arthritis pain relievers is substantial and growing. The arthritic therapeutic market, which includes a wide range of treatments for arthritis, was valued at $79.5 billion in 2022[5].

Forecasted Growth

This market is projected to reach $136.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.5% from 2023 to 2032[5]. The topical pain relief market, a subset of this broader market, is also expected to see significant growth, reaching $13.68 billion by 2028 at a CAGR of 6.2%[1].

Drivers of Market Growth

Increasing Prevalence of Arthritis

The rising prevalence of arthritis is a major driver of the market. According to the CDC, about 24.2% of women and 17.9% of men in the United States were told by a doctor that they had arthritis between 2019 and 2021. By 2040, it is projected that about 78 million adults will live with arthritis in the U.S. alone[2].

Aging Population

The growing geriatric population is another significant factor. The World Health Organization (WHO) estimates that there will be 1.4 billion people aged 60 years and over by 2030, which will increase the demand for arthritis treatments[5].

Advancements in Medical Technology

The development of new and innovative treatments, such as biologics, JAK inhibitors, and targeted synthetic DMARDs, is driving market growth. These newer therapies offer improved efficacy and safety profiles, attracting more patients and healthcare providers[2][3].

E-commerce and Home Delivery Models

The growth of e-commerce platforms and home delivery models has made arthritis pain relievers more accessible, contributing to the market's expansion[1].

Market Segmentation

By Type

The market is segmented into prescription pain relief and over-the-counter (OTC) pain relief. Prescription pain relievers, including biologics and targeted therapies, are expected to see significant growth due to their efficacy and the increasing number of patients seeking advanced treatments[1].

By Formulation

Topical pain relievers come in various formulations such as creams, gels, sprays, patches, and other forms. The patch segment is particularly growing due to its convenience and prolonged release of medication[1].

By Therapeutic

The market is divided into non-opioids and opioids. Non-opioids, including NSAIDs and other anti-inflammatory drugs, are widely used due to their safety profile and effectiveness in managing arthritis pain[1][5].

By Distribution Channel

Pharmacies and drug stores remain the primary distribution channels, but e-commerce and retail stores are gaining traction due to their convenience and accessibility[1].

Regional Analysis

North America

North America holds the largest revenue share in the arthritic therapeutic market due to its well-established healthcare infrastructure and advanced medical facilities. The region's robust economy enables significant investments in healthcare research and development[5].

Asia-Pacific

The Asia-Pacific region is expected to exhibit the fastest growth during the forecast period. This is driven by robust economic development, a rapidly expanding aging population, and improving healthcare infrastructure in countries like China and India[5].

Competitive Landscape

The arthritic therapeutic market is highly competitive, with key players such as AbbVie Inc., Pfizer, Amgen Inc., Bristol-Myers Squibb, and Eli Lilly and Company holding significant market positions. These companies have a strong geographical foothold and are continuously investing in research and development to introduce new and innovative treatments[5].

Price Projections

Current Pricing

The current pricing of arthritis pain relievers varies widely depending on the type of medication, formulation, and distribution channel. For instance, topical pain relievers can range from a few dollars to several hundred dollars per unit, depending on the brand and formulation[1].

Future Pricing Trends

Given the increasing demand and advancements in technology, prices are expected to remain competitive. However, premium-priced anti-TNF drugs and other targeted biologics are likely to maintain their high price points due to their efficacy and the lack of generic alternatives[3].

Cost Factors

The cost of arthritis pain relievers is influenced by several factors, including research and development costs, regulatory approvals, and market competition. The rising healthcare costs and the need for effective pain management solutions are also driving the pricing strategies of pharmaceutical companies[1][5].

Key Takeaways

  • Growing Market Size: The arthritic therapeutic market is expected to grow significantly, reaching $136.1 billion by 2032.
  • Increasing Prevalence: The rising prevalence of arthritis, especially among the aging population, is a major driver of market growth.
  • Technological Advancements: New and innovative treatments, such as biologics and JAK inhibitors, are driving market expansion.
  • Regional Growth: North America leads the market, but the Asia-Pacific region is expected to show the fastest growth.
  • Competitive Landscape: Key players are investing heavily in research and development to maintain their market positions.

FAQs

Q: What is the projected market size of the arthritic therapeutic market by 2032?

A: The arthritic therapeutic market is projected to reach $136.1 billion by 2032[5].

Q: Which region is expected to show the fastest growth in the arthritic therapeutic market?

A: The Asia-Pacific region is expected to exhibit the fastest growth during the forecast period[5].

Q: What are the main drivers of the arthritis pain reliever market?

A: The main drivers include the increasing prevalence of arthritis, the growing geriatric population, and advancements in medical technology[2][5].

Q: Which types of arthritis pain relievers are expected to see significant growth?

A: Prescription pain relievers, including biologics and targeted therapies, are expected to see significant growth due to their efficacy[1].

Q: How is the rise of e-commerce affecting the arthritis pain reliever market?

A: The growth of e-commerce platforms and home delivery models has made arthritis pain relievers more accessible, contributing to market expansion[1].

Sources

  1. The Business Research Company - Topical Pain Relief Market Size, Research Report 2024 - 2033
  2. GlobeNewswire - Rheumatoid Arthritis Drugs Market Size to Worth USD 27.38 Billion by 2033
  3. iHealthcareAnalyst - Global Rheumatoid Arthritis Drugs Market $53.1 Billion by 2031
  4. Biospace - Chronic Pain Market worth $115.51 Billion by 2031, Coherent Market Insights
  5. Allied Market Research - Arthritic Therapeutic Market Research, Growth | Forecast - 2032

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.